Journal article
Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients
C Dendle, RL Stuart, KR Polkinghorne, A Balloch, J Kanellis, J Ling, M Kummrow, C Moore, K Thursky, J Buttery, K Mulholland, PY Gan, S Holdsworth, WR Mulley
Transplant Infectious Disease | WILEY | Published : 2018
DOI: 10.1111/tid.12866
Abstract
Background: Conjugated pneumococcal vaccine is recommended for kidney transplant recipients, however, their immunogenicity and potential to trigger allograft rejection though generation of de novo anti-human leukocyte antigen antibodies has not been well studied. Methods: Clinically stable kidney transplant recipients participated in a prospective cohort study and received a single dose of 13-valent conjugate pneumococcal vaccine. Anti-pneumococcal IgG was measured for the 13 vaccine serotypes pre and post vaccination and functional anti-pneumococcal IgG for 4 serotypes post vaccination. Anti-human leukocyte antigen antibodies antibodies were measured before and after vaccination. Kidney tra..
View full abstractGrants
Funding Acknowledgements
CD received an unrestricted educational grant from Pfizer Inc. No other authors declare any disclosures.